Orion OYJ ORION B ORD SHS/  FI0009014377  /

London International
06/06/2024  21:00:00 Chg. - Volume Bid17:40:09 Ask17:40:09 Market Capitalization Dividend Y. P/E Ratio
38.74EUR - 69,555
Turnover: 2.72 mill.
-Bid Size: - -Ask Size: - 4.77 bill.EUR 3.63% 28.96

Business description

Orion is a globally operating Finnish developer of pharmaceuticals and diagnostic tests – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. It is continuously developing new drugs and treatment methods. The core therapy areas of Orion’s pharmaceutical R&D are central nervous system (CNS) disorders, oncology and respiratory for which Orion developes inhaled Easyhaler® pulmonary drugs. Orion's customers are mainly healthcare service providers and professionals such as specialist and general practitioners, veterinarians, pharmacies, hospitals, healthcare centres, clinics and laboratories. Consumers with pets are another important customer group. Orion's main market is Finland, where it is the clear market leader. Orion’s products are marketed in over a hundred countries, and the Group's own human pharmaceuticals sales organisation covers almost all key European markets. In other markets Orion’s products are sold by several collaboration partners. All of Orion's manufacturing plants and most of its R&D operations are in Finland. Orion’s headquarters are in Espoo.
 

Management board & Supervisory board

CEO
Liisa Hurme
Management board
Jari Karlson, Outi Vaarala, Satu Ahomäki, Virve Laitinen, Juhani Kankaanpää, Olli Huotari
Supervisory board
Mikael Silvennoinen, Ari Lehtoranta, Eija Ronkainen, Hilpi Rautelin, Kari Jussi Aho, Veli-Matti Mattila, Maziar Mike Doustdar, Karen Lykke Sørensen
 

Company data

Name: Orion Corporation
Address: Orionintie 1A,FI-02200 Espoo
Phone: +358-10-4261
Fax: -
E-mail: -
Internet: is.gd/3PivOU
Industry: Healthcare
Sector: Healthcare Providers
Sub sector: Healthcare Providers
End of financial year: 31/12
Free Float: 97.66%
IPO date: -

Investor relations

Name: Jari Karlson
IR phone: +358-10-426-2883
IR Fax: -
IR e-mail: -